TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in plasma 3‐methylhistidine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean time to full recovery regarding sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary composite outcome
Endpoint domain: Mortality/survival
Primary endpoint: success rates of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPQ score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: candidates for oral anticoagulation treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LDA at Year 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper limb function (CAHAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall bleeding complications
Endpoint domain: Adverse events/effects
Primary endpoint: Ease of use
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Reduction in subjective effects of morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: time interval to complete abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FMD value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum NO level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAM-D total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression-Improvement scale rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Insulin-like growth factor-1 (IGF-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-1RA (inflammatory biomarker)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Capacity to recognize facial expressions of emotions
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Processing speed for recognizing emotions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle strength stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease severity assessed with CGI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of complete response (no PONV, no rescue)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity >/=6/18
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra- and interobserver agreement for positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of EPI-GRE T2*-weighted sequence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge, attitudes, and self-reported behaviour for healthy eating and physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of active users
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: plasma docosapentaenoic acid (DPA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anterior height restored postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Impaired barrier function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: GCS score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute time-loss injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Quality of life dimensions
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total Peripheral Resistance (TPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peak intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: net increase in intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: conjunctival erythema
Endpoint domain: Adverse events/effects
Primary endpoint: EMGdi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PEEPi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Glycemic Index (GI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Glycemic Response (GR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: NAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for follow-up method
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Engaged in sexual intercourse in past 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Ventricular End-Systolic Volume (LVESV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: RTS (Response to Treatment Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SMR (Standard Metabolic Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resectability of hepatic lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent's QOL symptoms assessment improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Likelihood of child receiving inhaled corticosteroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of child missing school due to asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aortic systolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aortic pulse pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma concentrations of cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: low density lipoprotein (LDL)‐cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: transfusion requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Light sensitivity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease course shortening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak GH response to GHRP-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Activated partial thromboplastin time (aPTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Thrombin time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: reliance on mental health services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bodyweight reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 3-, 5-, 10-year survival rate
Endpoint domain: Mortality/survival
Primary endpoint: mean haemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: percentage of women feeling better and more energetic
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AUA symptom score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean peak uroflow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of symptomatic hypercalcaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite of all-cause death or new Q-wave myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: patient-oriented composite endpoint (POCE)
Endpoint domain: Mortality/survival
Primary endpoint: Physical performance during exercise heat stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum TYR concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daytime PTSD symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep improvements
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: remineralizing capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean VAS pain score at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients reporting pain at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State and Trait Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of severe granulocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Improved Macular Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDLc levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: oxLDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of acute mood events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute mood event-related hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Quality-adjusted life years (QALY) gains
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in predicted CVD risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: forgiveness ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prostate-specific antigen relapse-free survival (PSA-RFS)
Endpoint domain: Mortality/survival
Primary endpoint: KI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triglyceride decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: mean perfusion measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: area with increased perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: clinical irritation grades differentiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Predictive value of diagnostics for influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: full breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly defecation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hospital admission rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: overall incidence rate of dementia
Endpoint domain: Mortality/survival
Primary endpoint: AD incidence
Endpoint domain: Mortality/survival
Primary endpoint: Complement C3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in β‐cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: fewer condition-related inpatient bed days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: fewer condition-related ED visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: incidence of sialoadenitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of hypogeusia or taste loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of dry mouth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum high-sensitivity C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activity pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: supplemental analgesic requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient satisfactory rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: completeness of reporting
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maintenance of improvement or continued reduction in signs of photodamage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cutaneous side effects
Endpoint domain: Adverse events/effects
Primary endpoint: 24-hour urinary fluoride excretion/kg body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: paralytic ileus rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fatigue ratings
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: 7-day point prevalence abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: continuous abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: treatment default
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants achieving visual acuity of 20/25 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose disposal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary artery pressure (PA pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to walk around the novel path
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spatiotemporal gait parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttraumatic stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive avoidance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body image
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: depiction of the lymphatic system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: abnormalities of the lymphatic system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hospital admissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 2- and 5-year success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for detecting OSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for detecting OSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood Ratio Positive (LR+) for detecting OSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall physical and mental health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: DeMeester score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower esophageal sphincter (LES) resting pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quality-of-life index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 24 h urinary isoflavones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nonfluid weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: shoulder function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total incontinence frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: stress incontinence frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: PCAQ‐6 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AQLQ(S) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Follow-up rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Liver volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASLN detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reaction time in VSTM tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ApoA-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High-density lipoprotein cholesterol (HDL-C) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of large HDL particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-craniotomy pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total and activated leucocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Exhaled NO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AaOIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonic epithelial cell proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alteration of biological characteristics of explant dermal fibroblasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of inappropriate therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of inappropriate shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of inappropriate ATP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percentage of urine samples negative for opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days per week of illicit opioid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum consecutive weeks of opioid abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tmax values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rapid Virological Response (RVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological relapse rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: use of health care resources
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Continence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urgency symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of blood glucose tests greater than 11 mM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Standard deviation of blood glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severe toxicities grade 3/4
Endpoint domain: Adverse events/effects
Primary endpoint: Motor block initiation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First analgesic requirement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise capacity (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes